Chapter
Capstone Fund to Raise Additional $30M for MDMA-Assisted Psychotherapy Research
1:18:21 - 1:23:15 (04:54)
Non-profit organization, Multidisciplinary Association for Psychedelic Studies (MAPS), has raised over $80 million for their research on MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD), and is currently raising an additional $30 million, with a phase III cost estimate of roughly $65 million to get their treatment approved through the FDA and Health Canada. The highly driven, non-pharmaceutical salaried staff, and already available extensive research on MDMA and Ecstasy are contributing factors to the organization's efficient development process.
Clips
Rick Doblin, founder of the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses the cost and importance of developing MDMA into medicine, and how his organization is working towards FDA approval.
1:18:21 - 1:21:46 (03:25)
Summary
Rick Doblin, founder of the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses the cost and importance of developing MDMA into medicine, and how his organization is working towards FDA approval. Despite the high costs and extensive studies required, Doblin is passionate about the potential benefits of MDMA therapy for those affected by trauma and addiction.
ChapterCapstone Fund to Raise Additional $30M for MDMA-Assisted Psychotherapy Research
Episode#440: Rick Doblin — The Psychedelic Domino That Tips All Others
PodcastThe Tim Ferriss Show
MAPS, a mission-driven organization that works on developing safe and effective medicines, is funding their MDMA clinical trials efficiently with a total budget of around 65 million.
1:21:47 - 1:23:15 (01:28)
Summary
MAPS, a mission-driven organization that works on developing safe and effective medicines, is funding their MDMA clinical trials efficiently with a total budget of around 65 million. They have a team of passionate experts and they have already raised 35 million, $30 million more from Capstone, and profits are reinvested in the mission for further research.